Skip to content

Study · Not a test of the peptide alone · 1989

1 result

[The treatment of psoriasis patients with concomitant neurological symptoms].

Rakhmatov AB, Mirakhmedov UM

Vestnik dermatologii i venerologii1 Jan 1989

PMID2633552 (opens in a new tab)PepBankPUB-02633552
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome

    In psoriasis patients, earlobe cerebrolysin injection within multiple-modality treatment was reported as the most effective administration approach.

    In plain wordsIn psoriasis patients, earlobe cerebrolysin injection within combined treatment was reported as more effective than other routes.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRelative treatment effectiveness
    Study

    n: not reported in source

    Comparator
    Other administration routes
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Injection of the agent into the earlobe (according to auricular acupuncture technique) has proved to be the most effective and economic.
    1 context sentence
    Summary · context
    Cerebrolysin administered via various routes was used in the multiple-modality treatment of psoriasis patients.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.